LHFPL1

Across TCGA pan-cancer cohorts, LHFPL1 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of LHFPL1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where LHFPL1 RNA is repressed in tumor relative to normal tissue. In most cancer types LHFPL1 is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

THCA, COAD, and LUSC are the cancer types where LHFPL1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LHFPL1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	II,III,IV	−0.845	<.001	8	view →
COAD	All	IV	−0.155	<.001	8	view →
LUSC	Female	All	+1.296	<.001	7	view →
BRCA	Female	II,III,IV	−0.456	<.001	6	view →
HNSC	All	II,III,IV	−0.377	.002	6	view →
KIRC	Female	All	−0.152	.012	5	view →
UCEC	All	All	+0.406	.011	4	view →
LUAD	All	All	+0.264	<.001	4	view →
STAD	Male	II,III,IV	−0.099	.006	4	view →
READ	All	All	−0.151	.004	3	view →
PRAD	All	All	−0.407	<.001	2	view →
CHOL	All	All	+0.158	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

LHFPL1–THCA

Open the THCA breakdown →